Table 6.
Association between NAT2 genotypes and risk of NHL.
| Controls | Cases | ||||
|---|---|---|---|---|---|
| N(%) | N(%) | OR (95% CI)* | p | Acetylator phenotype | |
| NAT2*5B/*6A | 129(16.0) | 137(13.9) | 0.64 (0.40, 1.01) | 0.06 | Slow |
| NAT2*5/*5 | 27(3.3) | 55(5.6) | 1.16 (0.63, 2.13) | 0.6 | Slow |
| NAT2*5/*6 | 59(7.3) | 77(7.8) | 0.77 (0.45, 1.30) | 0.3 | Slow |
| NAT2*5B/*5B | 94(11.6) | 94(9.6) | 0.59 (0.36, 0.97) | 0.04 | Slow |
| NAT2*5B/*7B | 22(2.7) | 22(2.2) | 0.59 (0.29, 1.20) | 0.1 | Slow |
| NAT2*6/*6 | 19(2.4) | 26(2.6) | 0.88 (0.43, 1.81) | 0.7 | Slow |
| NAT2*6A/*6A | 46(5.7) | 52(5.3) | 0.66 (0.38, 1.17) | 0.2 | Slow |
| Other NAT2 slow-acetylator genotypes** | 56(6.9) | 59(6.0) | 0.67 (0.39, 1.15) | 0.1 | Slow |
| NAT2*4/*5 | 45(5.6) | 57(5.8) | 0.88 (0.50, 1.55) | 0.7 | Intermediate |
| NAT2*4/*5B | 88(10.9) | 151(15.3) | 1.04 (0.65, 1.68) | 0.9 | Intermediate |
| NAT2*4/*6 | 42(5.2) | 33(3.4) | 0.49 (0.27, 0.90) | 0.02 | Intermediate |
| NAT2*4/*6A | 92(11.4) | 92(9.3) | 0.61 (0.37, 0.99) | 0.04 | Intermediate |
| Other NAT2 intermediate-acetylator genotypes** | 39(4.8) | 57(5.8) | 1.13 (0.64, 2.01) | 0.7 | Intermediate |
| NAT2*4/*4 | 45(5.6) | 66(6.7) | 1.00 (reference) | Rapid | |
| Other NAT2 rapid-acetylator genotypes** | 5(0.6) | 6(0.6) | 0.97 (0.27, 3.49) | 1.0 | Rapid |
*
OR (95% CI) adjusted for age, sex, race, and study center.
**
Other NAT2 slow-acetylator genotypes (<2% prevalence among controls): NAT2*5/*7, NAT2*5A/*5B, NAT2*5A/*5C, NAT2*5A/*6A, NAT2*5A/*7B, NAT2*5B/*5C, NAT2*5C/*6A, NAT2*5C/*7B, NAT2*6/*7, NAT2*6A/*7B, NAT2*7/*7, NAT2*7B/*7B.
**
Other NAT2 intermediate-acetylator genotypes (<2% prevalence among controls): NAT2*4/*5A, NAT2*4/*5C, NAT2*4/*7, NAT2*4/*7B, NAT2*5B/*12A, NAT2*5B/*13, NAT2*5C/*12A, NAT2*6A/*12A, NAT2*6A/*13, NAT2*7B/*12A, NAT2*7B/*13.
**
Other NAT2 rapid-acetylator genotypes (<2% prevalence among controls): NAT2*12A/*13, NAT2*4/*12A, NAT2*4/*13.